Fig. 3.

Percentage change from month 0 to month 48 in lumbar spine BMD (a), total hip BMD (b), P1NP (c), and β-CTX (d). Data shown are for participants who had received romosozumab 210 mg QM from month 0 to month 24 (n = 35) and had received either placebo (n = 19) or denosumab 60 mg Q6M (N = 16) from month 24 to month 36, before receiving romosozumab 210 mg QM from month 36 to month 48. Data are mean (95% CI) for BMD and median (Q1, Q3) for P1NP and β-CTX. β-CTX, β-isomer of C-terminal telopeptide of type 1 collagen; BMD, bone mineral density; CI, confidence interval; P1NP, procollagen type 1 N-terminal propeptide; Q1, Q3, first and third quartiles; QM, monthly; Q6M, every 6 months